Call +44 (0)1904 798634 or +44 (0)7550 079918

Leading provider of life science market reports and research services

OpportunityAnalyzer: Small Cell Lung Cancer (SCLC) - Opportunity Analysis and Forecasts to 2024

Be the first to review this product

OpportunityAnalyzer: Small Cell Lung Cancer (SCLC) - Opportunity Analysis and Forecasts to 2024

Summary

Initially considered a curable disease due to substantial sensitivity to first-line...
You can choose to pay by purchase order during checkout

Availability: In stock

$10,995.00

* Required Fields

You can choose to pay by purchase order during checkout
GlobalData.

Digital downloads direct to your inbox within 24 hours.

First class customer service from our team of experts.

Pay by credit card or request an invoice

Product Description

Details

OpportunityAnalyzer: Small Cell Lung Cancer (SCLC) - Opportunity Analysis and Forecasts to 2024

Summary

Initially considered a curable disease due to substantial sensitivity to first-line chemotherapies, small cell lung cancer (SCLC) remains a fatal disease with poor outcomes due to high relapse rates, with the majority of patients surviving one year or less after diagnosis. Unlike non-small cell lung cancer (NSCLC), in which major advances in treatment have been made following the approval of several targeted therapies, the field of SCLC has seen little advancement for several decades.

For the purposes of this report, GlobalData considers the Global SCLC market to include SCLC-specific drug sales in the 7MM (US, 5EU [France, Germany Italy, Spain, and the UK], and Japan). The current market across these countries is dominated by the sale of major generic chemotherapy regimens. GlobalData estimated that the Global SCLC market was valued at $198m in 2014. Following the expected approval of new agents over the forecast period, relapsed/refractory patients will have significantly improved therapeutic options leading to rapid uptake of these drugs. The increased use of branded therapies in treatment-na

Additional Information

Additional Information

Publisher name GlobalData.
Format PDF
Page count 230
Publication date 1 Jan 2016
Table of contents 1 Table of Contents
1 Table of Contents 9
1.1 List of Tables 13
1.2 List of Figures 17
2 Introduction 19
2.1 Catalyst 19
2.2 Related Reports 19
2.3 Upcoming Related Reports 20
3 Disease Overview 21
3.1 Etiology and Pathophysiology 21
3.1.1 Etiology 21
3.1.2 Pathophysiology 22
3.2 Symptoms 23
3.3 Diagnosis 24
3.4 Clinical Staging 26
3.5 Prognostic Factors 29
3.6 Quality of Life 29
4 Epidemiology 31
4.1 Disease Background 31
4.2 Risk Factors and Comorbidities 32
4.3 Global Trends 34
4.3.1 Incidence 34
4.3.2 Stage at Diagnosis 34
4.3.3 Relative Survival 34
4.4 Forecast Methodology 35
4.4.1 Sources Used 36
4.4.2 Sources Not Used 42
4.4.3 Forecast Assumptions and Methods 43
4.5 Epidemiological Forecast for SCLC (2014-2024) 47
4.5.1 Diagnosed Incident Cases of SCLC 47
4.5.2 Age-Specific Incident Cases of SCLC 49
4.5.3 Sex-Specific Incident Cases of SCLC 51
4.5.4 Age-Standardized Incidence of SCLC 53
4.5.5 Stage-Specific Incident Cases of SCLC 54
4.5.6 Five-Year Diagnosed Prevalent Cases of SCLC 55
4.5.7 Five-Year Diagnosed Prevalent Cases of SCLC Segmented by Stage 57
4.6 Discussion 58
4.6.1 Epidemiological Forecast Insight 58
4.6.2 Limitations of the Analysis 60
4.6.3 Strengths of the Analysis 61
5 Current Treatment Options 62
5.1 First-Line Therapy 62
5.2 Second-Line Therapy 68
5.3 Subsequent Lines of Therapy 71
6 Unmet Needs Assessment and Opportunity Analysis 73
6.1 Overview 73
6.2 Unmet Needs Analysis 74
6.2.1 Early Diagnosis of Disease 74
6.2.2 Therapies That Improve Overall Survival 76
6.2.3 More Effective and Tolerable Therapies for Relapsed/Refractory Disease 78
6.2.4 Discovery of Predictive Biomarkers and Understanding of the Underlying Causes of Disease 79
6.2.5 Smoking Cessation Programs 80
6.3 Opportunity Analysis 81
6.3.1 Standardized Methods for Biomarker Testing 81
6.3.2 Developing Therapies with an Improved Safety Profile 82
6.3.3 Understanding the Mechanisms Underlying the Rapid Emergence of Drug and Radiation Resistance 83
6.3.4 Targeting Pathways Unique to Cancer Stem Cells 84
7 R&D Strategies 85
7.1 Overview 85
7.1.1 Deconstructing the SCLC Genome 85
7.1.2 New Diagnostic Approaches 89
7.1.3 Reformulation of Available Chemotherapeutic Agents 91
7.1.4 Combination Therapy 92
7.2 Clinical Trial Design 93
7.2.1 Evolution of Endpoints for Cancer Immunotherapy Trials 95
7.2.2 Health-Related Quality of Life Endpoints in Oncology Clinical Trials 96
7.2.3 Design of Current Phase II and III Trials in SCLC 97
8 Pipeline Assessment 99
8.1 Overview 99
8.2 Promising Drugs in Clinical Development 100
8.2.1 Alisertib (MLN8237) 101
8.2.2 MGN-1703 107
8.2.3 NGR-hTNF 112
8.2.4 Opdivo (nivolumab) 117
8.2.5 Roniciclib (BAY 1000394) 124
8.2.6 Sabarubicin (MEN10755) 130
8.2.7 Sacituzumab Govitecan (IMMU-132) 134
8.2.8 Sutent (sunitinib malate) 140
8.2.9 Tarextumab (OMP-59R5) 145
8.2.10 Yervoy (ipilimumab) 150
8.3 Innovative Early-Stage Approaches 158
8.3.1 Rovalpituzumab Tesirine (SC16LD6.5) 159
8.3.2 Keytruda (pembrolizumab) 160
8.3.3 PARP Inhibitors 161
8.3.4 Lurbinectedin (PM01183) 163
9 Pipeline Valuation Analysis 165
9.1 Clinical Benchmark of Key Pipeline Drugs 165
9.2 Commercial Benchmark of Key Pipeline Drugs 169
9.3 Competitive Assessment 173
9.4 Top-Line 10-Year Forecast 174
9.4.1 US 178
9.4.2 5EU 179
9.4.3 Japan 181
10 Appendix 183
10.1 Bibliography 183
10.2 Abbreviations 202
10.3 Methodology 207
10.4 Forecasting Methodology 207
10.4.1 Diagnosed SCLC Patients 207
10.4.2 Percent Drug-Treated Patients 208
10.4.3 Drugs Included in Each Therapeutic Class 209
10.4.4 Launch and Patent Expiry Dates 209
10.4.5 General Pricing Assumptions 210
10.4.6 Average Body Weight and Surface Area Across 7MM 211
10.4.7 Individual Drug Assumptions 212
10.4.8 Generic Erosion 224
10.5 Physicians and Specialists Included in this Study 225
10.6 About the Authors 226
10.6.1 Authors 226
10.6.2 Epidemiologist 227
10.6.3 Global Director of Therapy Analysis and Epidemiology 227
10.6.4 Global Head of Healthcare 228
10.7 About GlobalData 229
10.8 Disclaimer 229

Reviews

Write Your Own Review

Only registered users can write reviews. Please, log in or register

Product Tags

Product Tags

Use spaces to separate tags. Use single quotes (') for phrases.